Full Patient Information
...
Full Patient Information
17 PATIENT COUNSELING INFORMATION
Adverse Reactions
Advise patients to report to their healthcare provider if they experience any signs or symptoms consistent with:
- •
- Injection Site Reactions [see Warnings and Precautions (5.2)]
- •
- Potential for Exacerbation of Zinc Deficiency [see Warnings and Precautions (5.3)]
- •
- Acute Tubulointerstitial Nephritis [see Contraindications (4), Warnings and Precautions (5.4)]
- •
- Clostridium difficile-Associated Diarrhea [see Warnings and Precautions (5.5)]
- •
- Bone Fracture [see Warnings and Precautions (5.6)]
- •
- Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.7)]
- •
- Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.8)]
- •
- Hepatic Effects [see Warnings and Precautions (5.9)]
- •
- Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.10)]
Drug Interactions
Instruct patients to inform their healthcare provider of any other medications they are currently taking, including rilpivirine-containing products [Contraindications (4)] and high dose methotrexate [Warnings and Precautions (5.14)].
Pregnancy
Advise a pregnant woman of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)].
Did you find an answer to your question?
Yes
No